1. Therapeutic effects of açaí seed extract on hepatic steatosis in high-fat diet-induced obesity in male mice: a comparative effect with rosuvastatin.
- Author
-
Tavares TB, Santos IB, de Bem GF, Ognibene DT, da Rocha APM, de Moura RS, Resende AC, Daleprane JB, and da Costa CA
- Subjects
- Animals, Diet, High-Fat, Disease Models, Animal, Dyslipidemias metabolism, Dyslipidemias prevention & control, Hyperglycemia metabolism, Hyperglycemia prevention & control, Hypolipidemic Agents isolation & purification, Lipid Metabolism drug effects, Liver metabolism, Liver pathology, Male, Mice, Inbred C57BL, Non-alcoholic Fatty Liver Disease etiology, Non-alcoholic Fatty Liver Disease metabolism, Non-alcoholic Fatty Liver Disease pathology, Obesity etiology, Obesity metabolism, Obesity pathology, Oxidative Stress drug effects, Plant Extracts isolation & purification, Seeds, Euterpe chemistry, Hydroxymethylglutaryl-CoA Reductase Inhibitors pharmacology, Hypolipidemic Agents pharmacology, Liver drug effects, Non-alcoholic Fatty Liver Disease prevention & control, Obesity drug therapy, Plant Extracts pharmacology, Rosuvastatin Calcium pharmacology
- Abstract
Objectives: Obesity is considered a risk factor for the development of non-alcoholic fatty liver disease (NAFLD). The hydroalcoholic extract obtained from the açai seed (ASE), rich in proanthocyanidins, has been shown a potential body weight regulator with antioxidant properties. This study aimed to investigate the therapeutic effect of ASE in obesity-associated NAFLD and compare it with Rosuvastatin., Methods: Male C57BL/6 mice received a high-fat diet or standard diet for 12 weeks. The treatments with ASE (300 mg/kg per day) or rosuvastatin (20 mg/kg per day) began in the eighth week until the 12th week., Key Findings: Our data show that the treatments with ASE and rosuvastatin reduced body weight and hyperglycaemia, improved lipid profile and attenuated hepatic steatosis in HFD mice. ASE and Rosuvastatin reduced HMGCoA-Reductase and SREBP-1C and increased ABGC8 and pAMPK expressions in the liver. Additionally, ASE, but not Rosuvastatin, reduced NPC1L1 and increased ABCG5 and PPAR-α expressions. ASE and rosuvastatin increased SIRT-1 expression and antioxidant defence, although only ASE was able to decrease the oxidative damage in hepatic tissue., Conclusions: The therapeutic effect of ASE was similar to that of rosuvastatin in reducing dyslipidemia and hepatic steatosis but was better in reducing oxidative damage and hyperglycaemia., (© 2020 Royal Pharmaceutical Society.)
- Published
- 2020
- Full Text
- View/download PDF